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Background. Infective endocarditis (IE) is a life-threatening disease. Its epidemiological profile has substantially changed in recent
years although 1-year mortality is still high. Despite advances in medical therapy and surgical technique, there is still uncertainty
on the best management and on the timing of surgical intervention. The objective of this review is to produce further insight into
the short- and long-term outcomes of patients with IE, with a focus on those presenting cerebrovascular complications.
1. Introduction
The term endocarditis refers to an inflammation of the
inner tissues of the heart or endocardium that can lead to
life-threatening complications if untreated. Although non-
infective endocarditis can develop from the deposition of
platelet and fibrin thrombi within the four cardiac chambers,
the pathology is usually caused by a vegetation colonized
by microorganisms, a condition referred to as “infective
endocarditis” (IE) [1]. Infective endocarditis is associated
with high morbidity and mortality, since the patient may
suffer from valvular incompetence leading to heart failure,
myocardial abscess, and embolism. The yearly incidence of
IE is estimated between 30 and 100 episodes per million
persons [2] and is expected to increase in the coming
years considering the growing number of interventional
procedures, device implantations and other health-related
procedures that can provide an access to the bloodstream for
the microorganisms. In fact, health-care related procedures
are responsible for over one-third of IE in Western countries
[2]. Since major predisposing factors are abnormalities in the
endocardium including congenital heart defects, rheumatic
valvular disease, bicuspid or calcific aortic valves, mitral
valve prolapse and hypertrophic cardiomyopathy, a peak of
incidence of 145/million persons has been found in the elderly
(70-80 years), which are particularly vulnerable also due to
reduced efficiency of the immune and hemostatic system
[3, 4]. The latter finding may be also partially explained by
the increased age of patients undergoing surgical procedures
of any kind, mainly with the growth of minimally invasive
cardiac procedures [5–8]. Moreover, despite trends toward
earlier diagnosis and surgical intervention, the 1-year mortal-
ity from IE has not improved in over 2 decades, ranging from
15 to 30% [9]. Around 30% of patients with Staphylococcu
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bacteremia will develop IE at any time. Nowadays prosthetic
heart valves, hemodialysis, venous catheters, immunosup-
pression, pacemakers, and other intracardiac devices and
intravenous drug abuse, jointly with the previously men-
tioned advanced age that often implies comorbidities and
frailties of the patient, are considered the main risk factors
for the development of IE. In detail, almost 75% of IE
patients have structural valve abnormalities (e.g., mitral valve
prolapse, bicuspid aortic valve) or have implanted prosthetic
valve [10].
IE was traditionally assessed following the “Duke crite-
ria”, but recently these criteria have been updated to the state
of the art by 2015 ESC guidelines [11]. Briefly, when IE is
suspected, transthoracic echocardiography (TTE) should be
performed first, followed by transesophageal echocardiogra-
phy (TOE) in those cases of uncertainty or negative results
in which the clinician highly suspects the presence of bac-
terial vegetation. Magnetic resonance imaging (MRI), com-
puted tomography (CT) and positron emission tomography-
computed tomography (PET-CT) may be helpful to detect
microbial vegetation in difficult echocardiographic settings
and, importantly, may detect symptomatic or asymptomatic
distal site of embolization.The identification of the microbial
agent from blood samples is the necessary following step.
If blood cultures are positive, then mass spectrometry and
agar culturing should be performed to identify the infective
agent; if blood cultures are negative, serological analyses by
PCR should be performed. If those are still negative, the use
of antinuclear, antiphospholipid, and anti-Pork antibodies is
then recommended [11]. Antimicrobial susceptibility testing
concludes this diagnostic algorithm and allows the clinician
to administrate an effective antibiotic therapy to the patient
(Figure 1).
Surgery should be considered as part of the therapy for IE
as it is required in 25% to 50% of cases in the acute phase [12,
13]. Surgery is more frequently indicated on prosthetic valve
endocarditis (PVE) than in native valve endocarditis (NVIE).
Selecting for urgent surgery those patients that are exposed
to the highest risk of death before decompensation dramat-
ically ameliorates the course of the disease and improves
prognosis. In fact, patient comorbidities and preoperative
status, together with the specific infecting microorganism
and intracardiac anatomy, are crucial for the surgical out-
come, as confirmed by preoperative echocardiogram and
intraoperative inspection. The major risk factors for death
are heart failure (HF), periannular complications, and/or S.
aureus infection [14].This latter pathogen, compared to other
bacteria, is more frequently associated with neurological
complications. Clinically relevant neurological complications
are present in up to 30% of the cases but may occur in
35-60% as silent embolization that may lead to cerebral or
subarachnoidal hemorrhage, silent ischemic attacks, menin-
gitis, toxic encephalopathy, and eventually brain abscess.
Practice guidelines have been recently elaborated to assess an
appropriate timing for surgery (urgent versus emergent), to
avoid progressive HF, irreversible structural damage, and to
prevent systemic embolism (Table 1) [11].
The aim of this review is to focus on the decision-making
process in the setting of IE and concomitant neurological
events like ischemic stroke or intracranial hemorrhage. The
management of these patients is difficult and complex and
requires a multidisciplinary approach (Endocarditis Team).
2. Infective Endocarditis and
Neurological Complications
Intracardiac vegetationmay result in life-threatening embolic
events. The overall risk of peripheral embolism is 20-50%,
and once antibiotic therapy is started, this risk decreases to 6-
21% [15]. The brain and the spleen are the most frequent sites
of embolization in left-sided IE, while pulmonary embolism
is frequent in native right-sided and pacemaker lead IE. The
overall incidence of embolic stroke during IE ranges from 10
to 50% and its associated mortality is over 30%. However,
embolic events may be silent in up to 50% of the patients,
in particular those affecting the spleen and the brain. In
this large amount of cases, the diagnosis relies mainly on
noninvasive imaging, among which echocardiography has
a prominent role, allowing to determine size, location, and
evolution of the vegetation also in response to antibiotic
therapy in a fast and economical way. The risk of emboliza-
tion is related to specific microorganisms as S. aureus, S.
bovis, or Candida spp., previous embolism, multivalvular
IE, and biological markers [15–17]. The size and mobility
of the vegetation are powerful independent predictors of
a new embolic event [18] and a recent study found that
the risk of neurological complications was particularly high
in patients with large (> 30 mm length) vegetation [19].
Vegetation located on the anterior leaflet of the mitral valve
may embolize more often. Neurological manifestations can
occur both before or after the diagnosis of IE is made and
recurrent events can develop also later during the infection.
Clinical presentation is variable and includes stroke, transient
ischemic attack, intracerebral or subarachnoid hemorrhage,
brain abscess, meningitis, and toxic encephalopathy. Focal
signs predominate and evidence supports that clinically silent
cerebral embolisms occur in 35–60% of IE patients [20].
3. Timing of Surgery
Evidence regarding the optimal time interval between stroke
and cardiac surgery is conflicting. During the acute phase of
ischemic stroke, the occurrence of hypotension and the need
for full anticoagulation during cardiopulmonary bypass may
worsen the neurological status, due to an augmentated risk
of hemorrhagic transformation and a potential extension of
the ischemic lesion [21]. However, several studies suggested
that the risk of postoperative neurological deterioration after
early surgery is lower than previously expected even in
patients with cerebral hemorrhage. After an ischemic stroke,
cardiac surgery is not contraindicated unless the neurological
prognosis is judged poor [22]. In the study from the ICE-PCS
collaboration, the outcome of 58 patients with an ischemic
stroke undergoing early surgery (<7days) was compared with
late surgery. After risk adjustment, surgery was associated
with a nonsignificant increase of in-hospital mortality [23].
This finding has been interpreted by both theAmericanHeart















































MRI: magnetic resonance imaging
MS: mass spectrometry
NVIE: natal valve infective endocarditis
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Figure 1: A schematic representation of the diagnostic algorithm according to the 2015 ESC guidelines.
Association (AHA) and the European Society of Cardiology
(ESC) to suggest that surgery can be safely performed if
indicated, although stroke remains a common reason for
denial or delaying surgical intervention in everyday practice.
In contrast, transient ischemic attack or silent embolism
should not delay surgery that is indicated for other reasons. If
cerebral hemorrhage has been excluded by cerebral computed
tomography and neurological damage is not severe (i.e.,
coma), surgery could be performed with low neurological
risk (mortality 3–6%) and chances of complete neurological
recovery [24].
On the contrary, in cases of hemorrhagic lesions, recent
European guidelines recommend delaying surgery for at least
1 month. A recent Japanese multicenter study [25] shows that
delayed surgery (2 weeks after cerebral infarction) results in a
higher incidence of in-hospital death in the group of patients
affected by nonhemorrhagic cerebral infarction. Patients who
had surgery between 15 and 28 days or after 29 days from
the onset of the embolic event had higher incidences of in-
hospital death compared with those who had surgery within
7 days. On the other hand, in the group of patients affected
by hemorrhagic cerebral infarction, those who had surgery
between 8 and 21 days or after 22 days after the onset had
a lower incidence of in-hospital death compared with those
who had surgery within 7 days. Even if these differences were
not statistically significant, early surgery appears safe but very
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Table 1: Indications and timing of surgery in left-sided valve IE (native valve endocarditis and prosthetic valve endocarditis) ESC-EACTS
2015 Guidelines [11].
Heart failure Surgical Timing
Aortic or mitral NVE or PVE with severe acute regurgitation, obstruction or fistula causing refractory
pulmonary oedema or cardiogenic shock
Emergency
(Class I - Level of
recommendation B)
Aortic or mitral NVE or PVE with severe regurgitation or obstruction causing symptoms of HF or
echocardiographic signs of poor haemodynamic tolerance
Urgent
(Class I - Level of
recommendation B)
Uncontrolled infection
Locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation)
Urgent
(Class I - Level of
recommendation B)
Infection caused by fungi or multiresistant organisms
Urgent/Elective
(Class I - Level of
recommendation C)
Persisting positive blood cultures despite appropriate antibiotic therapy and adequate control of septic
metastatic foci
Urgent
(Class II - Level of
recommendation A)
PVE caused by staphylococci or non-HACEK gram-negative bacteria
Urgent/Elective
(Class II - Level of
recommendation A)
Prevention of embolism
Aortic or mitral NVE or PVE with persistent vegetation >10 mm after one or more embolic episode despite
appropriate antibiotic therapy
Urgent
(Class I - Level of
recommendation B)
Aortic or mitral NVE with vegetation >10 mm, associated with severe valve stenosis or regurgitation, and low
operative risk
Urgent
(Class II - Level of
recommendation A)
Aortic or mitral NVE or PVE with isolated very large vegetation (> 30 mm)
Urgent
(Class II - Level of
recommendation A)
Aortic or mitral NVE or PVE with isolated large vegetation (>15 mm) and no other indication for surgery
Urgent
(Class II - Level of
recommendation B)
early surgery (before 7 days) should be avoided in patients
with hemorrhagic infarction. However, the evidence is still
low with this regard.
4. Anticoagulant Therapy
The treatment of stroke patients with anticoagulant therapy
may lead to hemorrhagic transformation in 51-71% of the
cases, considerably worsening the severity of the neurologic
symptoms and the prognosis [26, 27]. However, the chance
of developing this condition is also depending on the size,
location, and cause of the stroke [28]. The management of
these patients depends on the amount of bleeding and may
require clot evacuation for themost severe cases. An eventual
fatal outcome is typically due to brain hemorrhage and
central nervous system complications. Normally, thrombus
organization requires two weeks and the administration
of anticoagulant agents should be well pondered, strictly
monitoring prothrombin-time (PT) during the gradual rein-
troduction of the therapy [29]. Interestingly, the therapeutic
safety and benefits of anticoagulation in patients with native
valve infective endocarditis (NVIE) that are suffering from
ischemic stroke are still debated [30].
Prosthetic valve infective endocarditis (PVE) occurs at
a rate of about 2% per year, and mortality ranges from
50 to 80%. The management of mechanical valve PVE,
whether medical or surgical, remains a challenging area as
outcomes are frequently dismal. One of the salient issues
in the medical management of mechanical valve PVE is
the use of anticoagulant therapy, which is sometimes rec-
ommended to prevent atherothrombotic complications in
case of mechanical valve prosthesis or presence of atrial
fibrillation. However, it is recommended to avoid all form
of anticoagulation in those patients suffering from PVE
caused by S. aureus that have recently been affected by
a neuroembolic event. In fact, S. aureus PVE is far more
lethal than the forms caused by other infective agents,
and anticoagulation should be avoided during the first two
weeks of antibiotic therapy, and an eventual reintroduction
carefully considered [31]. Some authors argue that the use
of anticoagulants in the setting of an infected mechanical
prosthetic valve increases the potential risk of secondary
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cerebral hemorrhage in the event of an embolic stroke. In
contrast, others affirm that anticoagulant therapy should
not be discontinued in mechanical valve PVE because of
the increased thromboembolic risk. Patients with a large
infarcted area, uncontrolled hypertension, evidence of coag-
ulopathy, or possible hemorrhagic transformation should
be considered for discontinuation of anticoagulant therapy,
since in some cases the benefits may be outweighed by the
risk of hemorrhage.
5. Conclusions
Preoperative neurological events represent a conflicting situ-
ation for the treating team. Patients with neurological events
frequently present with heart failure, uncontrolled infection,
and the risk of further embolization if large vegetation is
present. Furthermore, there is a risk of progression of neu-
rological damage if patients are on antithrombotic therapy or
undergo cardiac surgery as full anticoagulation is mandatory
for cardiopulmonary bypass. In this conflicting setting, the
timing for surgery is still a matter of concern and there still
exists uncertainty with regard to the right timing for surgery.
Well-designed and adequately powered randomized studies
are difficult to organize due to a number of factors including
ethical issues. Concluding remarks include the following:
(i) The emphasis on “early surgery” differs mainly
between European and US practice guidelines. The ESC
guidelines distinguish emergency surgery (performed within
24 h), urgent surgery (within a few days), and elective
surgery (after 1 to 2 weeks of antibiotic therapy), with surgery
advised on an urgent basis for most of the cases. In contrast,
the AHA guidelines define early surgery as “during initial
hospitalization and before completion of a full course of
antibiotics.”
(ii) In the case of ischemic stroke, early surgery, even
within 72 hours, may improve prognosis without increasing
the rate of hemorrhage conversion [32].
(iii) If required because of hemodynamic instability, in
case of hemorrhagic lesions, surgery may be performed after
careful evaluation of sizes and etiologies by a multidisci-
plinary discussion within 4 weeks of the hemorrhagic event
if patients are neurologically viable. In a number of studies,
the preoperative time interval between the neurological
event and surgery was found to be shorter in nonsurvivors,
but a short preoperative time tends to be associated with
severe hemodynamic impairment and ongoing sepsis, which
are associated with higher mortality. The plan of action
for patients with minor bleeding or minor hemorrhagic
conversion of an ischemic stroke remains open to clinical
judgment.
(iv) The eventual discontinuation of anticoagulant ther-
apy should be considered carefully for every single case,
evaluating whether the risk of hemorrhage outweighs the
benefit of continuing the therapy.
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